[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA49796C2 - Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція - Google Patents

Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція

Info

Publication number
UA49796C2
UA49796C2 UA96020442A UA96020442A UA49796C2 UA 49796 C2 UA49796 C2 UA 49796C2 UA 96020442 A UA96020442 A UA 96020442A UA 96020442 A UA96020442 A UA 96020442A UA 49796 C2 UA49796 C2 UA 49796C2
Authority
UA
Ukraine
Prior art keywords
preparing
paroxetine hydrochloride
treating
pharmaceutical composition
anhydrate
Prior art date
Application number
UA96020442A
Other languages
English (en)
Russian (ru)
Inventor
Віктор Вітольд Джейсвікз
Ніл Ворд
Original Assignee
Смітклайн Бічам П.Л.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA49796(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by Смітклайн Бічам П.Л.С. filed Critical Смітклайн Бічам П.Л.С.
Publication of UA49796C2 publication Critical patent/UA49796C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Цей винахід стосується ангідрату пароксетин гідрохлориду, вільного від зв'язаного пропан-2-олу, кількох його форм, способам його отримання, новим проміжним сполукам, підходящим для його отримання, і методам лікування і/або профілактики певних захворювань шляхом припису препарату за цим винаходом тим, хто його потребує.
UA96020442A 1995-02-06 1996-02-05 Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція UA49796C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (1)

Publication Number Publication Date
UA49796C2 true UA49796C2 (uk) 2002-10-15

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96020442A UA49796C2 (uk) 1995-02-06 1996-02-05 Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція

Country Status (47)

Country Link
EP (3) EP0808314B1 (uk)
JP (2) JP2915338B2 (uk)
KR (1) KR100289885B1 (uk)
CN (3) CN1289496C (uk)
AR (2) AR001982A1 (uk)
AT (1) AT407528B (uk)
AU (2) AU4786496A (uk)
BE (1) BE1009112A3 (uk)
BG (1) BG62967B1 (uk)
BR (1) BR9600534A (uk)
CA (4) CA2211522C (uk)
CH (3) CH689804A5 (uk)
CZ (1) CZ297171B6 (uk)
DE (3) DE69621777T2 (uk)
DK (2) DK11996A (uk)
DZ (1) DZ1989A1 (uk)
ES (1) ES2114471B1 (uk)
FI (3) FI111544B (uk)
FR (1) FR2730232B1 (uk)
GR (1) GR1002466B (uk)
HK (1) HK59397A (uk)
HU (1) HUP9600255A1 (uk)
IE (1) IE80500B1 (uk)
IL (1) IL117035A (uk)
IT (1) IT1289532B1 (uk)
LU (1) LU88711A1 (uk)
LV (1) LV11618B (uk)
MA (1) MA23802A1 (uk)
MC (1) MC2411A1 (uk)
MX (1) MX9600484A (uk)
MY (1) MY132529A (uk)
NL (1) NL1002248C2 (uk)
NO (3) NO301009B1 (uk)
NZ (1) NZ280943A (uk)
OA (1) OA10261A (uk)
PL (1) PL189247B1 (uk)
PT (1) PT101827B (uk)
RO (1) RO112426B1 (uk)
RU (1) RU2125052C1 (uk)
SE (1) SE521084C2 (uk)
SG (1) SG43787A1 (uk)
SI (2) SI21923B (uk)
SK (1) SK283608B6 (uk)
TR (1) TR199600096A2 (uk)
TW (1) TW503238B (uk)
UA (1) UA49796C2 (uk)
WO (1) WO1996024595A1 (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (en) * 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
WO1998002556A2 (en) * 1996-07-15 1998-01-22 Smithkline Beecham Plc Screening for and use of an esterase for a stereospecific resolution
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
DK0994872T3 (da) * 1997-06-10 2001-05-28 Synthon Bv 4-phenylpiperidin-forbindelser
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
EP1064282A1 (en) * 1998-03-16 2001-01-03 Smithkline Beecham Plc Crystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
PL345885A1 (en) * 1998-08-07 2002-01-14 Smithkline Beecham Plc Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
AU1397900A (en) * 1998-11-30 2000-06-19 Smithkline Beecham Plc Mixed paroxetine propan-2-ol solvates
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
DE50011819D1 (de) * 1999-03-12 2006-01-12 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
WO2002022609A1 (fr) * 2000-09-14 2002-03-21 Asahi Glass Company, Limited Procede de production de sel de paroxetine sensiblement exempt de solvant organique
IL163593A0 (en) * 2002-02-22 2005-12-18 Teva Pharma Preparation of paroxetine involving novel intermediates
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
AU4332896A (en) 1996-08-15
RO112426B1 (ro) 1997-09-30
AU701518C (en) 2006-12-07
MX198371B (uk) 2000-08-29
CA2210023A1 (en) 1996-08-07
DE69621777D1 (de) 2002-07-18
CN1289496C (zh) 2006-12-13
NO20015070D0 (no) 2001-10-18
DE69631298T2 (de) 2004-11-18
NL1002248A1 (nl) 1996-08-06
BG62967B1 (bg) 2000-12-29
PL312646A1 (en) 1996-08-19
JPH08245620A (ja) 1996-09-24
NL1002248C2 (nl) 1996-09-11
EP0808314A1 (en) 1997-11-26
NO301009B1 (no) 1997-09-01
BG100333A (bg) 1996-08-30
NO20015070L (no) 1996-08-07
PT101827B (pt) 1997-08-29
CN1143643A (zh) 1997-02-26
CA2168829C (en) 1997-12-16
NO970939L (no) 1996-08-07
FI960519A0 (fi) 1996-02-05
LV11618B (en) 1997-04-20
RU2125052C1 (ru) 1999-01-20
IL117035A0 (en) 1996-09-12
IT1289532B1 (it) 1998-10-15
IL117035A (en) 2000-02-29
HU9600255D0 (en) 1996-03-28
EP1136490B1 (en) 2004-01-07
PL189247B1 (pl) 2005-07-29
CH688353A5 (de) 1997-08-15
NO970939D0 (no) 1997-02-28
DE19603797C2 (de) 1998-11-12
ATA21096A (de) 2000-08-15
AR036856A2 (es) 2004-10-06
CN1090187C (zh) 2002-09-04
FR2730232B1 (fr) 1997-08-01
NZ280943A (en) 1997-01-29
PT101827A (pt) 1996-09-30
DE19603797A1 (de) 1996-08-14
CA2210022C (en) 2005-09-13
BE1009112A3 (fr) 1996-11-05
JP2915338B2 (ja) 1999-07-05
NO960472D0 (no) 1996-02-05
SI9600036B (sl) 2006-12-31
NO301009B3 (uk) 2003-01-06
CZ32096A3 (en) 1996-08-14
SI21923A (sl) 2006-06-30
DK200100223A (uk) 2001-02-12
EP1136490A1 (en) 2001-09-26
TW503238B (en) 2002-09-21
NO311519B1 (no) 2001-12-03
SE521084C2 (sv) 2003-09-30
ES2114471A1 (es) 1998-05-16
SG43787A1 (en) 1997-11-14
MY132529A (en) 2007-10-31
LV11618A (lv) 1996-12-20
EP1378508A1 (en) 2004-01-07
LU88711A1 (fr) 1996-08-23
MC2411A1 (fr) 1996-12-02
HUP9600255A1 (en) 1997-03-28
AU701518B2 (en) 1999-01-28
DE69631298D1 (de) 2004-02-12
ITMI960203A0 (uk) 1996-02-05
FI20030370A (fi) 2003-03-12
AU4786496A (en) 1996-08-27
FI960519A (fi) 1996-08-07
OA10261A (en) 1997-09-19
HK59397A (en) 1997-05-16
MA23802A1 (fr) 1996-10-01
CN1636993A (zh) 2005-07-13
GR1002466B (el) 1996-11-06
CA2211522C (en) 1999-12-07
CA2168829A1 (en) 1996-08-07
SK283608B6 (sk) 2003-10-07
TR199600096A2 (tr) 1996-08-21
SE9600406L (sv) 1996-08-07
CH689804A5 (de) 1999-11-30
EP0808314B1 (en) 2002-06-12
NO960472L (no) 1996-08-07
FR2730232A1 (fr) 1996-08-09
KR100289885B1 (ko) 2001-05-15
FI111544B (fi) 2003-08-15
SI9600036A (en) 1996-10-31
IE80500B1 (en) 1998-08-12
SI21923B (sl) 2006-12-31
IE960104A1 (en) 1996-08-07
FI20030162A (fi) 2003-02-03
CA2210023C (en) 1999-02-09
KR960031409A (ko) 1996-09-17
JPH11228571A (ja) 1999-08-24
CZ297171B6 (cs) 2006-09-13
CN1216055C (zh) 2005-08-24
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
SK14396A3 (en) 1996-11-06
CA2211522A1 (en) 1996-08-07
ES2114471B1 (es) 1999-08-16
ITMI960203A1 (it) 1997-08-05
AT407528B (de) 2001-04-25
CH689229A5 (de) 1998-12-31
MX9600484A (es) 1997-01-31
AR001982A1 (es) 1998-01-07
CA2210022A1 (en) 1996-08-07
BR9600534A (pt) 1997-05-13
CN1310180A (zh) 2001-08-29
DE69621777T2 (de) 2003-01-02
SE9600406D0 (sv) 1996-02-05
WO1996024595A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
UA49796C2 (uk) Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція
MX9707879A (es) Derivados de piperazina sustituidos novedosos que tienen actividad antagonista de receptor de taquinina.
HK1054236A1 (en) Intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
ATE398618T1 (de) Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
ZA965997B (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
IL114185A (en) Substituted alkyldiamine derivatives pharmaceutical compositions containing them and process for their preparation
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
GR3031544T3 (en) New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety